* Avanos Medical Inc AVNS.N AVNS.K is expected to show a
fall in quarterly revenue when it reports results on November
2.
* The Alpharetta, Georgia-based company is expected to report a
0.2% decrease in revenue to $185.34 million from $185.7 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Avanos Medical Inc is
for earnings of 30 cents per share. For the same quarter last
year, the company reported earnings of 21 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Avanos Medical
Inc is $45, about 29.8% above its last closing price
of $31.57.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 30 2021 0.23 0.23 0.21 Missed -10
Mar. 31 2021 0.18 0.19 0.23 Beat 24.3
Dec. 31 2020 0.22 0.22 0.28 Beat 29.2
Sep. 30 2020 0.11 0.10 0.21 Beat 110
Jun. -0.08 -0.10 0.13 Beat 230
30 2020
Mar. 31 2020 0.15 0.16 0.16 Met 1.6
Dec. 31 2019 0.32 0.32 0.34 Beat 7.5
Sep. 30 2019 0.31 0.31 0.30 Missed -4
This summary was machine generated October 29 at 17:00 GMT. All
figures in US dollars unless otherwise stated